Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil Source: Eur Respir J 2005; 26: Suppl. 49, 563s Year: 2005
Dose-ranging study to assess the efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1037-1049 Year: 2002
Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004
Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Source: Eur Respir J 2007; 29: 469-475 Year: 2007
A randomised, controlled trial of bosentan in severe COPD Source: Eur Respir J 2008; 32: 619-628 Year: 2008
Safety and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Long-term sitaxsentan therapy in PAH Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004
Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 204s Year: 2005
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights Source: Eur Respir J 2015; 46: 414-421 Year: 2015
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020 Year: 2020
Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data. Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017
Long term effects of transitioning from sitaxsentan to ambrisentan in pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation III Year: 2010
No relevant drug-drug interaction between inhaled NVA237 and oral cimetidine Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007